The Experts below are selected from a list of 3516 Experts worldwide ranked by ideXlab platform
Julia A Haller - One of the best experts on this subject based on the ideXlab platform.
-
intraoperative ketorolac and Eye Pain after vitreoretinal surgery a prospective randomized placebo controlled study
Retina-the Journal of Retinal and Vitreous Diseases, 2004Co-Authors: Sharon Fekrat, Sarah H Elsing, Sharath C Raja, Peter A Campochiaro, Marta J Marsh, Eugene De Juan, Julia A HallerAbstract:PURPOSE: To compare the efficacy of one intraoperative dose of intravenous ketorolac tromethamine to saline placebo in controlling postoperative Eye Pain, nausea, and sedation following vitreoretinal surgery. STUDY DESIGN: Prospective, randomized, placebo-controlled clinical trial. METHODS: One hundred fourteen vitreoretinal surgical patients were randomized over a 7-month period to a single intraoperative intravenous dose of ketorolac tromethamine or placebo. All patients underwent surgery with intravenous sedation and retrobulbar anesthetic injection and had access to a standard postoperative analgesic regimen. After 2 and 5 hours, Eye Pain, nausea, and sedation levels were recorded using a standard visual analog scale. Analgesic requirements were tabulated. RESULTS: Patients given ketorolac were significantly less likely to have postoperative Eye Pain than were placebo-treated patients (P = 0.0043). Fewer ketorolac patients required postoperative analgesia than placebo patients did (P < 0.0001). Four ketorolac patients (7%) required a narcotic compared to 11 placebo patients (20%) (P < 0.0001). Fewer ketorolac patients experienced nausea and sedation than placebo patients did, but this difference was not statistically significant. CONCLUSION: Ketorolac tromethamine is an effective nonnarcotic choice for postoperative Pain control following vitreoretinal surgery. Pain control is particularly important in this group of patients, whose compliance with postoperative procedures and positioning may significantly affect surgical outcome.
-
Eye Pain after vitreoretinal surgery a prospective study of 185 patients
Retina-the Journal of Retinal and Vitreous Diseases, 2001Co-Authors: Sharon Fekrat, Sarah H Elsing, Sharath C Raja, Peter A Campochiaro, De Juan E, Julia A HallerAbstract:PURPOSE: To assess subjective levels of Eye Pain, nausea, and sedation following vitreoretinal surgery performed with intravenous sedation and retrobulbar anesthesia. METHODS: One hundred eighty-five consecutive patients who underwent vitreoretinal surgery and had access to a standard postoperative analgesic regimen prospectively quantified levels of Eye Pain, nausea, and sedation 2 hours and 5 hours after surgery by using a standard visual analog scale. Analgesic requests were recorded. Responses were statistically analyzed. RESULTS: Fifty-six percent of patients had some Eye Pain after vitreoretinal surgery; 48% of patients requested an analgesic within 5 hours after surgery. Twenty-seven percent of patients required narcotic analgesia. There was a significant relationship between the presence of Eye Pain and surgery duration of >2 hours (P 2 hours), will request Pain medication within 5 hours after surgery; one half of these patients will need narcotic analgesia for Pain control. Narcotics may result in nausea and sedation.
Sharon Fekrat - One of the best experts on this subject based on the ideXlab platform.
-
intraoperative ketorolac and Eye Pain after vitreoretinal surgery a prospective randomized placebo controlled study
Retina-the Journal of Retinal and Vitreous Diseases, 2004Co-Authors: Sharon Fekrat, Sarah H Elsing, Sharath C Raja, Peter A Campochiaro, Marta J Marsh, Eugene De Juan, Julia A HallerAbstract:PURPOSE: To compare the efficacy of one intraoperative dose of intravenous ketorolac tromethamine to saline placebo in controlling postoperative Eye Pain, nausea, and sedation following vitreoretinal surgery. STUDY DESIGN: Prospective, randomized, placebo-controlled clinical trial. METHODS: One hundred fourteen vitreoretinal surgical patients were randomized over a 7-month period to a single intraoperative intravenous dose of ketorolac tromethamine or placebo. All patients underwent surgery with intravenous sedation and retrobulbar anesthetic injection and had access to a standard postoperative analgesic regimen. After 2 and 5 hours, Eye Pain, nausea, and sedation levels were recorded using a standard visual analog scale. Analgesic requirements were tabulated. RESULTS: Patients given ketorolac were significantly less likely to have postoperative Eye Pain than were placebo-treated patients (P = 0.0043). Fewer ketorolac patients required postoperative analgesia than placebo patients did (P < 0.0001). Four ketorolac patients (7%) required a narcotic compared to 11 placebo patients (20%) (P < 0.0001). Fewer ketorolac patients experienced nausea and sedation than placebo patients did, but this difference was not statistically significant. CONCLUSION: Ketorolac tromethamine is an effective nonnarcotic choice for postoperative Pain control following vitreoretinal surgery. Pain control is particularly important in this group of patients, whose compliance with postoperative procedures and positioning may significantly affect surgical outcome.
-
Eye Pain after vitreoretinal surgery a prospective study of 185 patients
Retina-the Journal of Retinal and Vitreous Diseases, 2001Co-Authors: Sharon Fekrat, Sarah H Elsing, Sharath C Raja, Peter A Campochiaro, De Juan E, Julia A HallerAbstract:PURPOSE: To assess subjective levels of Eye Pain, nausea, and sedation following vitreoretinal surgery performed with intravenous sedation and retrobulbar anesthesia. METHODS: One hundred eighty-five consecutive patients who underwent vitreoretinal surgery and had access to a standard postoperative analgesic regimen prospectively quantified levels of Eye Pain, nausea, and sedation 2 hours and 5 hours after surgery by using a standard visual analog scale. Analgesic requests were recorded. Responses were statistically analyzed. RESULTS: Fifty-six percent of patients had some Eye Pain after vitreoretinal surgery; 48% of patients requested an analgesic within 5 hours after surgery. Twenty-seven percent of patients required narcotic analgesia. There was a significant relationship between the presence of Eye Pain and surgery duration of >2 hours (P 2 hours), will request Pain medication within 5 hours after surgery; one half of these patients will need narcotic analgesia for Pain control. Narcotics may result in nausea and sedation.
Sarah H Elsing - One of the best experts on this subject based on the ideXlab platform.
-
intraoperative ketorolac and Eye Pain after vitreoretinal surgery a prospective randomized placebo controlled study
Retina-the Journal of Retinal and Vitreous Diseases, 2004Co-Authors: Sharon Fekrat, Sarah H Elsing, Sharath C Raja, Peter A Campochiaro, Marta J Marsh, Eugene De Juan, Julia A HallerAbstract:PURPOSE: To compare the efficacy of one intraoperative dose of intravenous ketorolac tromethamine to saline placebo in controlling postoperative Eye Pain, nausea, and sedation following vitreoretinal surgery. STUDY DESIGN: Prospective, randomized, placebo-controlled clinical trial. METHODS: One hundred fourteen vitreoretinal surgical patients were randomized over a 7-month period to a single intraoperative intravenous dose of ketorolac tromethamine or placebo. All patients underwent surgery with intravenous sedation and retrobulbar anesthetic injection and had access to a standard postoperative analgesic regimen. After 2 and 5 hours, Eye Pain, nausea, and sedation levels were recorded using a standard visual analog scale. Analgesic requirements were tabulated. RESULTS: Patients given ketorolac were significantly less likely to have postoperative Eye Pain than were placebo-treated patients (P = 0.0043). Fewer ketorolac patients required postoperative analgesia than placebo patients did (P < 0.0001). Four ketorolac patients (7%) required a narcotic compared to 11 placebo patients (20%) (P < 0.0001). Fewer ketorolac patients experienced nausea and sedation than placebo patients did, but this difference was not statistically significant. CONCLUSION: Ketorolac tromethamine is an effective nonnarcotic choice for postoperative Pain control following vitreoretinal surgery. Pain control is particularly important in this group of patients, whose compliance with postoperative procedures and positioning may significantly affect surgical outcome.
-
Eye Pain after vitreoretinal surgery a prospective study of 185 patients
Retina-the Journal of Retinal and Vitreous Diseases, 2001Co-Authors: Sharon Fekrat, Sarah H Elsing, Sharath C Raja, Peter A Campochiaro, De Juan E, Julia A HallerAbstract:PURPOSE: To assess subjective levels of Eye Pain, nausea, and sedation following vitreoretinal surgery performed with intravenous sedation and retrobulbar anesthesia. METHODS: One hundred eighty-five consecutive patients who underwent vitreoretinal surgery and had access to a standard postoperative analgesic regimen prospectively quantified levels of Eye Pain, nausea, and sedation 2 hours and 5 hours after surgery by using a standard visual analog scale. Analgesic requests were recorded. Responses were statistically analyzed. RESULTS: Fifty-six percent of patients had some Eye Pain after vitreoretinal surgery; 48% of patients requested an analgesic within 5 hours after surgery. Twenty-seven percent of patients required narcotic analgesia. There was a significant relationship between the presence of Eye Pain and surgery duration of >2 hours (P 2 hours), will request Pain medication within 5 hours after surgery; one half of these patients will need narcotic analgesia for Pain control. Narcotics may result in nausea and sedation.
Sharath C Raja - One of the best experts on this subject based on the ideXlab platform.
-
intraoperative ketorolac and Eye Pain after vitreoretinal surgery a prospective randomized placebo controlled study
Retina-the Journal of Retinal and Vitreous Diseases, 2004Co-Authors: Sharon Fekrat, Sarah H Elsing, Sharath C Raja, Peter A Campochiaro, Marta J Marsh, Eugene De Juan, Julia A HallerAbstract:PURPOSE: To compare the efficacy of one intraoperative dose of intravenous ketorolac tromethamine to saline placebo in controlling postoperative Eye Pain, nausea, and sedation following vitreoretinal surgery. STUDY DESIGN: Prospective, randomized, placebo-controlled clinical trial. METHODS: One hundred fourteen vitreoretinal surgical patients were randomized over a 7-month period to a single intraoperative intravenous dose of ketorolac tromethamine or placebo. All patients underwent surgery with intravenous sedation and retrobulbar anesthetic injection and had access to a standard postoperative analgesic regimen. After 2 and 5 hours, Eye Pain, nausea, and sedation levels were recorded using a standard visual analog scale. Analgesic requirements were tabulated. RESULTS: Patients given ketorolac were significantly less likely to have postoperative Eye Pain than were placebo-treated patients (P = 0.0043). Fewer ketorolac patients required postoperative analgesia than placebo patients did (P < 0.0001). Four ketorolac patients (7%) required a narcotic compared to 11 placebo patients (20%) (P < 0.0001). Fewer ketorolac patients experienced nausea and sedation than placebo patients did, but this difference was not statistically significant. CONCLUSION: Ketorolac tromethamine is an effective nonnarcotic choice for postoperative Pain control following vitreoretinal surgery. Pain control is particularly important in this group of patients, whose compliance with postoperative procedures and positioning may significantly affect surgical outcome.
-
Eye Pain after vitreoretinal surgery a prospective study of 185 patients
Retina-the Journal of Retinal and Vitreous Diseases, 2001Co-Authors: Sharon Fekrat, Sarah H Elsing, Sharath C Raja, Peter A Campochiaro, De Juan E, Julia A HallerAbstract:PURPOSE: To assess subjective levels of Eye Pain, nausea, and sedation following vitreoretinal surgery performed with intravenous sedation and retrobulbar anesthesia. METHODS: One hundred eighty-five consecutive patients who underwent vitreoretinal surgery and had access to a standard postoperative analgesic regimen prospectively quantified levels of Eye Pain, nausea, and sedation 2 hours and 5 hours after surgery by using a standard visual analog scale. Analgesic requests were recorded. Responses were statistically analyzed. RESULTS: Fifty-six percent of patients had some Eye Pain after vitreoretinal surgery; 48% of patients requested an analgesic within 5 hours after surgery. Twenty-seven percent of patients required narcotic analgesia. There was a significant relationship between the presence of Eye Pain and surgery duration of >2 hours (P 2 hours), will request Pain medication within 5 hours after surgery; one half of these patients will need narcotic analgesia for Pain control. Narcotics may result in nausea and sedation.
Peter A Campochiaro - One of the best experts on this subject based on the ideXlab platform.
-
intraoperative ketorolac and Eye Pain after vitreoretinal surgery a prospective randomized placebo controlled study
Retina-the Journal of Retinal and Vitreous Diseases, 2004Co-Authors: Sharon Fekrat, Sarah H Elsing, Sharath C Raja, Peter A Campochiaro, Marta J Marsh, Eugene De Juan, Julia A HallerAbstract:PURPOSE: To compare the efficacy of one intraoperative dose of intravenous ketorolac tromethamine to saline placebo in controlling postoperative Eye Pain, nausea, and sedation following vitreoretinal surgery. STUDY DESIGN: Prospective, randomized, placebo-controlled clinical trial. METHODS: One hundred fourteen vitreoretinal surgical patients were randomized over a 7-month period to a single intraoperative intravenous dose of ketorolac tromethamine or placebo. All patients underwent surgery with intravenous sedation and retrobulbar anesthetic injection and had access to a standard postoperative analgesic regimen. After 2 and 5 hours, Eye Pain, nausea, and sedation levels were recorded using a standard visual analog scale. Analgesic requirements were tabulated. RESULTS: Patients given ketorolac were significantly less likely to have postoperative Eye Pain than were placebo-treated patients (P = 0.0043). Fewer ketorolac patients required postoperative analgesia than placebo patients did (P < 0.0001). Four ketorolac patients (7%) required a narcotic compared to 11 placebo patients (20%) (P < 0.0001). Fewer ketorolac patients experienced nausea and sedation than placebo patients did, but this difference was not statistically significant. CONCLUSION: Ketorolac tromethamine is an effective nonnarcotic choice for postoperative Pain control following vitreoretinal surgery. Pain control is particularly important in this group of patients, whose compliance with postoperative procedures and positioning may significantly affect surgical outcome.
-
Eye Pain after vitreoretinal surgery a prospective study of 185 patients
Retina-the Journal of Retinal and Vitreous Diseases, 2001Co-Authors: Sharon Fekrat, Sarah H Elsing, Sharath C Raja, Peter A Campochiaro, De Juan E, Julia A HallerAbstract:PURPOSE: To assess subjective levels of Eye Pain, nausea, and sedation following vitreoretinal surgery performed with intravenous sedation and retrobulbar anesthesia. METHODS: One hundred eighty-five consecutive patients who underwent vitreoretinal surgery and had access to a standard postoperative analgesic regimen prospectively quantified levels of Eye Pain, nausea, and sedation 2 hours and 5 hours after surgery by using a standard visual analog scale. Analgesic requests were recorded. Responses were statistically analyzed. RESULTS: Fifty-six percent of patients had some Eye Pain after vitreoretinal surgery; 48% of patients requested an analgesic within 5 hours after surgery. Twenty-seven percent of patients required narcotic analgesia. There was a significant relationship between the presence of Eye Pain and surgery duration of >2 hours (P 2 hours), will request Pain medication within 5 hours after surgery; one half of these patients will need narcotic analgesia for Pain control. Narcotics may result in nausea and sedation.
